Invesco Preferred ETF vs Twist Bioscience Corp — how do they compare? Invesco Preferred ETF trades at $10.38, while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| PGX | TWST | |
|---|---|---|
52-Week High | $11.87 | $153.10 |
52-Week Low | $10.46 | $24.16 |
Market Cap | — | $8.42B |
Sector | — | Health |
Enterprise Value | — | $8.35B |
Signals from Pluang's Aura AI — not financial advice
PGX trades at $10.49 with no change in the last 24 hours. Technical indicators show a bearish trend from moving averages but bullish signals from oscillators, with support at $10 and resistance at $11. Recent corporate actions include dividends declared for H1-26 and H2-26, though key financial ratios are unavailable for fundamental assessment.
The outlook remains uncertain due to limited financial data. Opportunities include dividend income, but risks stem from the lack of transparency in earnings and valuation metrics. Investors should seek updated SEC filings for a clearer picture of the company's health and growth prospects.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Trailing returns across standard periods
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →